Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Blood Donations Falling Sharply among Young People
September 29, 2008
- PhRMA to Present Comments on Draft GL for Biosimilars Announced by Korosho
September 29, 2008
- Number of Lifestyle Disease-Free Persons Increases for First Time
September 29, 2008
- Draft GL Announced for Approval of Biosimilars
September 29, 2008
- Measles Vaccination Rates Remain Under 40% in Teenagers: Korosho Survey
September 29, 2008
- BUSINESS NEWS IN BRIEF
September 29, 2008
- Long-term Hospitalization for Schizophrenia Causes Problems in IADL
September 29, 2008
- DTP Focused on at 2008 IFPW General Membership Meeting
September 29, 2008
- Many Physicians Lack Accurate Knowledge about Medicinal Narcotics
September 29, 2008
- Pure Pharma Business Model Approaching the End: Mr K. Masuzoe
September 29, 2008
- Avastin Effective in Patients with or without K-ras Gene Mutation
September 29, 2008
- Quintiles to Provide Lab Data Directly Comparable with Those from Other Countries
September 29, 2008
- Mylan to Increase Number of MRs to 300, Open 4 More Offices
September 29, 2008
- Astellas Ties Up with Maxygen to Develop Drugs for Autoimmune Diseases, Transplant Rejection
September 29, 2008
- More Prescriptions than Expected Prohibit Use of Generics: Mr Urushibata
September 29, 2008
- Erbitux Launched by Merck Serono and Bristol-Myers
September 29, 2008
- Draft Ordinance Published in Preparation for Full Enforcement of Amended PAL
September 29, 2008
- NanoCarrier Ties Up with Taiwan Company for Nanoplatin
September 29, 2008
- Pfizer to Start Clinical Trial for Fibromyalgia
September 29, 2008
- Bristol-Myers Applies for Abatacept
September 29, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…